🔗 Share this article

This year's Nobel Prize in Physiology or Medicine was granted for revolutionary findings that illuminate how the body's defense network targets harmful infections while protecting the body's own cells.

A trio of esteemed researchers—from Japan Shimon Sakaguchi and US scientists Mary Brunkow and Dr. Ramsdell—received this accolade.

Their research uncovered unique "sentinels" within the immune system that eliminate malfunctioning defense cells that could attacking the organism.

These findings are now paving the way for new therapies for autoimmune diseases and malignancies.

The winners will divide a prize fund worth 11 million SEK.

Crucial Findings

"The work has been decisive for comprehending how the immune system functions and why we do not all suffer from severe self-attack conditions," commented the chair of the Nobel Committee.

The team's research explain a fundamental question: How does the defense system defend us from numerous invaders while keeping our healthy cells intact?

The immune system employs white blood cells that search for indicators of disease, even viruses and germs it has never encountered.

Such cells utilize detectors—called receptors—that are produced randomly in a vast number of variations.

That gives the defense network the capacity to combat a wide array of threats, but the unpredictability of the process inevitably produces white blood cells that may attack the body.

Security Guards of the Immune System

Scientists earlier understood that some of these problematic defense cells were destroyed in the thymus—where white blood cells mature.

This year's Nobel Prize honors the discovery of regulatory T-cells—known as the body's "peacekeepers"—which patrol the body to neutralize other immune cells that assault the healthy cells.

It is known that this process malfunctions in self-attack conditions such as type-1 diabetes, MS, and RA.

A prize committee stated, "The findings have established a new field of investigation and accelerated the creation of innovative treatments, for instance for cancer and autoimmune diseases."

In cancer, regulatory T-cells block the body from fighting the growth, so studies are focused on lowering their quantity.

For autoimmune diseases, trials are testing increasing regulatory T-cells so the organism is not under attack. A similar method could also be effective in minimizing the risks of organ transplant rejection.

Innovative Studies

Professor Sakaguchi, from a Japanese institution, performed tests on rodents that had their thymus removed, causing self-attack conditions.

He showed that introducing defense cells from other animals could prevent the illness—implying there was a system for preventing defenders from harming the body.

Mary Brunkow, from the Institute for Systems Biology in a US city, and Fred Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were studying an genetic autoimmune disease in mice and humans that resulted in the identification of a genetic factor vital for how T-regs operate.

"Their pioneering work has revealed how the immune system is kept in check by regulatory T cells, stopping it from mistakenly targeting the healthy cells," said a prominent physiology specialist.

"This research is a remarkable illustration of how basic physiological study can have far-reaching consequences for public health."